Antibe Therapeutics Reports 2017 Year-End Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) filed its financial and operating results Friday, July 28 for the
fourth quarter and the year ended March 31, 2017. The Corporation's audited 2017 financial statements, MD&A and AIF are
available on SEDAR.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing
molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a
safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent
global need for a safer, non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin.
www.antibethera.com.
Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products
servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of
knowledge and experience in the Canadian medical device industry. Citagenix Inc. is active in 15 countries, operating in Canada
through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com.
Forward Looking Information
This news release includes certain forward-looking statements, which may include, but are not limited to, the completion of
financing transactions and the licensing and development of drugs and medical devices. Any statements contained herein that are not
statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will",
"anticipate", "believe", "plan", "estimate", "expect", "intend", "propose" and similar expressions. Forward-looking statements
involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ
materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from
those anticipated in this news release include, but are not limited to, failure to raise the full Offering amount, failure to
obtain TSX Venture Exchange approval for the transactions described herein, and risks associated with drug and medical device
development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the
reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable
law.
Antibe Therapeutics Inc.
Dan Legault, 416-473 4095
Chief Executive Officer
dan.legault@antibethera.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170728005820/en/